Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) aims to maximize asset value by selling a 30% stake in China-US Shanghai Squibb Pharmaceutical Co., Ltd. for no less than 1.023 billion yuan [1][8]. Group 1: Asset Sale Details - The company plans to transfer its 30% stake in China-US Shanghai Squibb through a public listing, with a minimum transfer price set at approximately 1.023 billion yuan [1][8]. - The potential buyer submitted a bid of 480 million USD for 100% of China-US Shanghai Squibb, valuing Shanghai Pharmaceuticals' 30% stake at approximately 144 million USD [2][7]. - The company’s stake in China-US Shanghai Squibb has a book cost of about 256 million yuan, indicating a potential profit of over 767 million yuan from the sale [9][10]. Group 2: Financial Performance and R&D Investment - Shanghai Pharmaceuticals has invested over 10 billion yuan annually in R&D since 2018, totaling approximately 107.23 billion yuan from 2021 to 2024 [12][13]. - The company reported a net profit attributable to shareholders exceeding 5 billion yuan in the first three quarters of 2025, reflecting a year-on-year increase of 26.96% [4][13]. - The company has achieved significant R&D milestones, including the approval of a new hypertension drug and the initiation of Phase III clinical trials for a new drug for ALS [3][13]. Group 3: Market Position and Business Model - Shanghai Pharmaceuticals is recognized as the second-largest pharmaceutical commercial enterprise in China and the largest provider of imported drugs, vaccines, and medical devices [12]. - The company’s revenue is primarily derived from pharmaceutical distribution, which accounted for 91.5% of total revenue in the first half of 2025, amounting to approximately 1.296 billion yuan [12]. - The company maintains a stable asset-liability ratio, which was 62.14% as of September 2025, consistent with historical levels [14].

Group 1 - The company plans to transfer 30% equity stake in its subsidiary, China-America Shanghai Bristol-Myers Squibb Pharmaceutical Co., Ltd., through public listing at a minimum price of 1.023 billion yuan [1] - The purpose of the transaction is to optimize the investment structure and maximize asset value, with the final price determined by the public listing results [1][2] - The current ownership structure of China-America Bristol-Myers Squibb includes 60% held by Bristol-Myers Squibb (China) Investment Co., Ltd., 30% by the company, and 10% by China National Pharmaceutical Group Asset Management Co., Ltd. [1] Group 2 - Bristol-Myers Squibb (China) Investment Co., Ltd. intends to sell its 60% stake in China-America Bristol-Myers Squibb, with a potential buyer expected to submit a confirmation bid by June 2025 for a total acquisition price of 480 million USD, equivalent to 1.44 billion yuan for the company's 30% stake [1] - The company believes that achieving an exit through market-based pricing will better maximize asset value and protect the interests of all shareholders, especially minority shareholders [2]

Core Viewpoint - Shanghai Pharmaceuticals plans to transfer its 30% stake in the subsidiary China-U.S. Shanghai Bristol-Myers Squibb Pharmaceutical Co., Ltd. through a public listing, with a minimum transfer price of 1.023 billion yuan [1] Group 1: Company Actions - The company will no longer hold any equity in China-U.S. Shanghai Bristol-Myers Squibb after the transaction is completed [1] - The transfer price will be determined based on the results of the public listing, following necessary state-owned asset evaluation procedures [1] Group 2: Financial Impact - The transaction is not expected to have a significant impact on the company's normal operations and financial status [1] - The move is aimed at protecting state-owned asset rights and maximizing asset value, aligning with the interests of the company and all shareholders [1]

Group 1 - The core viewpoint of the article is that Shanghai Pharmaceuticals plans to optimize its investment structure by publicly transferring its 30% stake in Celgene Corporation through a public listing, with a minimum listing price of approximately RMB 1.023 billion [1] Group 2 - The transfer process will involve a public listing and must complete relevant state-owned asset evaluation management procedures [1] - The final transfer price will be determined based on the results of the public listing [1]